{
    "nct_id": "NCT05566795",
    "official_title": "LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy",
    "inclusion_criteria": "* Less than 25 years of age with LGG with known activating RAF alteration.\n* Histopathologic diagnosis of glioma or glioneuronal tumor.\n* At least one measurable lesion as defined by RANO criteria.\n* Meet indication for first-line systemic therapy.\nHealthy volunteers allowed\nMust have maximum age of 25 Years",
    "exclusion_criteria": "* Participant has any of the following tumor-histological findings:\n\n  1. Schwannoma\n  2. Subependymal giant cell astrocytoma (Tuberous Sclerosis)\n  3. Diffuse intrinsic pontine glioma, even if histologically diagnosed as World Health Organization (WHO) Grade I-II\n* Participant's tumor has additional pathogenic molecular alterations, including but not limited to a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration.\n* Known or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2).\n* Prior or ongoing nonsurgical anticancer therapy for this indication (eg, chemotherapy, oral/IV targeted therapy) including radiation.",
    "miscellaneous_criteria": ""
}